Notice to applicant for public dissemination of Clinical Trials scientific and regulatory data by Egyptian Drug Authority

Year 2024

Code: EDREX.NP.Bioinn.
Version No.1
Issue Date:
Effective date:

1. Introduction

As part of the cooperation between the Egyptian Drug Authority (EDA) and clinical trial specified entities, the Egyptian Drug Authority (EDA) publishes this guidance that included the rationale, approach, and procedure for publishing a summary clinical trial application (CTA) report which summarized from the pre-clinical studies and the previous clinical studies reports for the clinical trial submitted to EDA for evaluation after the grantee approval(s) in Egypt without the data confidentiality breaking.

2. Rational

Through implementation of this guidance for publication of clinical data, The Egyptian Drug Authority (EDA) aim to set the transparency that also led to:

- Increase public trustability and confidence in EDA scientific and enforcement of decision-making operation
- Avoidance of clinical trials duplication
- Encouragement of innovation and development of new medicinal products
- Public availability of the scientific data would enable independent secondary analysis of the scientific data reviewed by the Agency's scientific committees to determine medicines' benefits and risks, which was expected to lead to public-health benefits.

3. Procedure

3.1 Preparation of CT Application Summary Report

- A comprehensive summary report is created based on data from pre-clinical studies and previous clinical studies. This report serves as part of the clinical trial package submitted to the Egyptian Drug Authority (EDA) for review.
- The report is sent to the applicants through their legal delegates for notification and review before it is published.

3.2 Review by Sponsor or Legal Delegate

- The sponsor or their legal delegate reviews the CT application summary report. This step allows them to provide feedback or comments regarding the content of the report.
- **Timeline:** Any comments must be submitted to the administration of protocols and studies follow-up at EDA within **10 days** of receiving the report.

3.3 Publication on EDA Website

- The protocols and studies follow-up administration at the General Administration (GA) of CT at EDA reviews the comments received from the sponsor or legal delegate.
- After consideration of these comments, the CT application summary reports are published on the EDA website, making them accessible to relevant stakeholders.

3.4 Updating After Amendments

- If there are any substantial amendments made to the clinical medical research (study protocol) that have been approved by EDA, the CT application summary report will be updated accordingly.
- The updated report is then republished to reflect these changes, ensuring that all information remains current and accurate.

Flowchart of publication process



CT application(s) summary report

- **Protocol title:**
- **Protocol code number:**
- **Eudra-CT:**
- **Version:**
- **Date:**
- **Investigational Medicinal Product being tested:**

Biological ☐ **Pharmaceutical** ☐ **Innovative** ☐

Herbal medicine ☐ **Medical device** ☐

- **Sponsor:**
- **CRO:**
- **Indication:**
- **Investigator's brochure (IB)**
  Version:
  Date:
- **Name of all Sites:**
- **Name of PI(s):**
- **EDA approval date:**

- **Summary of pre-clinical studies:**
- **Summary of previous clinical studies:**
- **Protocol:**
  Phase: **I** ☐ **II** ☐ **III** ☐ **IV** ☐
  Objective(s):
  Rationale:
  Design:
- **Recommendation &/or Questions & Answers:**

- **Abbreviation:**